PDP1 and endometrial cancer: When comparing dose responses of PFAS‐exposed endometrial cancer cells treated with carboplatin only versus PDP + carboplatin, analyses illustrated that PDP in combination with lower doses of carboplatin (50–100 μM) significantly reduced survival fractions in some cases; however, when PDP was combined with higher doses of carboplatin (200–400 μM), several instances of increased survival fraction were observed compared to carboplatin only.